Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Mallinckrodt
AstraZeneca
Harvard Business School
Express Scripts

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tanespimycin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Tanespimycin?

Tanespimycin is an investigational drug.

There have been 33 clinical trials for Tanespimycin. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2008.

The most common disease conditions in clinical trials are Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, and Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Bristol-Myers Squibb, and Cancer Research UK.

Recent Clinical Trials for Tanespimycin
TitleSponsorPhase
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic CancerNational Cancer Institute (NCI)Phase 2
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First RelapseBristol-Myers SquibbPhase 3
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity CancerNational Cancer Institute (NCI)Phase 2

See all Tanespimycin clinical trials

Clinical Trial Summary for Tanespimycin

Top disease conditions for Tanespimycin
Top clinical trial sponsors for Tanespimycin

See all Tanespimycin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Boehringer Ingelheim
Baxter
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.